Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma

Complete title: A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN, INTENSITY-MODULATED RADIOTHERAPY, AND MK-3475 (PEMBROLIZUMAB) IN HIGH-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

Research Study Number NRG-HN003
 
Principal Investigator Cristina Rodriguez
 
Phase I

Research Study Description

This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head and neck. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab with cisplatin and intensity-modulated radiation therapy may work better in treating patients with squamous cell carcinoma of the head and neck.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number NRG-HN003
 
Contact Seattle Cancer Care Alliance Intake Office
 
Telephone 800-804-8824 / 206-606-1024
 

Keywords: Head and Neck Cancer; Laryngeal Cancer; Solid Tumors; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Neoplasms, Glandular and Epithelial; Carcinoma; Neoplasms, Squamous Cell

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials